

SPONSORSHIP AGREEMENT



Parties to this agreement:

Diabetesforeningen

Att.: Tanja Thybo
Stationsparken 24, st.tv
2600 Glostrup
CVR No. DK-35 23 15 28

(“Recipient”)

Novo Nordisk Denmark A/S

Att.: Christina Klyver Tikkanen
Kay Fiskers Plads 10, 7 floor
2300 København S
CVR No. 38180045

(“Novo Nordisk”)

1. Summary

1.1 Recipient’s request for support. The appendix titled “Recipient’s request for support” details the specifics of the Recipient’s activity(ies) (“the Activity”) supported by the sponsorship and purpose of the Activity.

Title of Activity	Fortsat udvikling af ”Diabetestotal.nu - Bred formidling af kvaliteten i behandlingen af diabetes i Danmark
The Sponsorship	Novo Nordisk will provide sponsorship amount DKK 500.000, including added tax if applicable to support the Recipient’s request. Novo Nordisk is the one of several sponsors of the activity.
Agreement Duration	This agreement starts on 31.10.2023 and expires after all obligations are fulfilled, unless terminated earlier.

2. Recipient’s Duties

2.1 Compliance with law and ethics. The Recipient shall comply with all applicable laws, rules, regulations, and professional standards, including those related to ethical business practices, bribery and corruption, among others. The Recipient will hold Novo Nordisk harmless against any claim or suit that arises in relation to any deviation from the above mentioned that is not due to any act or omission by Novo Nordisk.

2.2 Carry out the Activity with proper conduct. The Recipient shall carry out the Activity independently and in compliance with Novo Nordisk standards and industry codes, in Denmark called ENLI (Etisk nævn for lægemiddelindustrien).

No use of funds for entertainment	Do not use the sponsorship for leisure or social activities
Select qualified participants	Apply appropriate criteria to select participants in the Activity, including that any speakers, facilitators, and chairpersons are experts in the professional fields relevant to the Activity
Reasonable payment and awards	If sponsorship is used for awards or other payments to third parties, apply a reasonable rate, including following Fair Market Value for any payments to Healthcare Professionals (hereinafter refer to as ‘HCPs’) and patients
Reasonable choice of venue	Hold activities in a location suitable for the Activity with modest hospitality
Reasonable travel	If sponsorship is used for Activity-related travel, carry out within reasonable time and cost

- 2.3 Physical items provided as-is.** If Novo Nordisk donates physical items, the Recipient is solely responsible for the use of such items, and shall assure proper handling and storage of sponsored items after delivery. Novo Nordisk is not liable for the Recipient's use of sponsored items and is not required to carry insurance or take any other measures to protect sponsored items after delivery. Novo Nordisk provides such items as-is and without any representation or warranty of quality or performance.
- 2.4 Internal approvals.** The Recipient shall obtain all necessary approvals related to the receipt of the sponsorship.
- 2.5 Inform Novo Nordisk of changes.** The Recipient shall inform Novo Nordisk of any changes affecting the request for support. If Novo Nordisk determines the change affects its compliance requirements, Novo Nordisk may demand full or partial return of sponsorship, at the discretion of Novo Nordisk. In the case of return, the Recipient shall comply within 14 days.
- 2.6 Provide documentation within 1 month.** The Recipient shall provide Novo Nordisk with documentation that the sponsorship was used for its intended purpose, within 1 month of completion of the Activity. Novo Nordisk may request additional detailed documentation as needed.
- 2.7 Disclose Novo Nordisk as sponsorship provider.** The Recipient shall mention Novo Nordisk as the provider of the sponsorship in any public communications or advertising related to the Activity.
- 2.8 Do not use Novo Nordisk branding without approval.** The Recipient may not use Novo Nordisk's logo, trademarks or other corporate identity marks or materials without written approval of the use from Novo Nordisk.
- 2.9 Allow Novo Nordisk to use Recipient's logo.** The Recipient permits Novo Nordisk to use the Recipient's logo, trademarks or other corporate identity marks in any public communications or advertising related to Novo Nordisk's sponsorship.

3. Requirements for Financial Sponsorships

- 3.1 Payment after receipt of invoice.** Novo Nordisk will send payment after receipt of invoice to the Recipient's bank account via electronic transfer within 30 days of receiving a complete invoice. Send completed PDF invoice to: AP-Novo-Repas@novonordisk.com. Include the below information on the invoice:

- Recipient name and address
- Bank account for electronic payment: Account holder name, account number (IBAN), bank name and address, routing number or code (SWIFT/BIC in EU, ABA/ACH in USA)
- Date of invoice
- The Title of Activity and dates of activities covered by the invoice
- Sponsorship amount payable
- VAT or other tax amount payable
- Name of Novo Nordisk entity and address as stated in the introduction of this Agreement
- Novo Nordisk recipient of invoice as included below:

Name of Novo Nordisk invoice recipient Mona Rosenblad mail: RNDG@novonordisk.com

- 3.2 Refund unspent amounts.** The Recipient shall refund to Novo Nordisk any amounts not spent for the requested purposes, within 14 days after complete documentation of the Activity is provided.

4. Other Terms and Conditions

- 4.1 Require Public disclosures.** To comply with applicable transparency requirements, Novo Nordisk will collect and may disclose personal information, transfers of value and details of its payment to Healthcare Professionals ("HCPs"), Healthcare Organizations ("HCOs"), and Patient Organizations. In addition to the payment amount, such disclosure may also include Name, address, contact details, nature of relationship with Novo Nordisk, tax number or unique identifier.

The Recipient will publish information on the Sponsorship on the Recipient's webpage. The information will include the Sponsorship amount and, if applicable, any in kind transfer, cf. the Danish Pharmaceutical Promotional Act (Reklamebekendtgørelsen) § 21. The information must be available on the Recipient's webpage no later than one (1) month after the Recipient received the Sponsorship. The information must be publicly available for at least two (2) years.

- 4.2 **No incentive to prescribe or recommend.** The sponsorship made by Novo Nordisk indicates no incentive or obligation for the Recipient to prescribe, recommend or otherwise support Novo Nordisk's products or services.
- 4.3 **No conflict of interest.** Recipient states it is not aware of any conflict of interest related to its acceptance of the sponsorship and shall promptly inform Novo Nordisk if such conflict of interest is discovered.
- 4.4 **Compliance hotline.** The Recipient can report suspected misconduct through the Novo Nordisk compliance hotline. Information about using the hotline and examples of what to report can be found at [Report suspected misconduct \(novonordisk.com\)](https://novonordisk.com).
- 4.5 **Termination for breach.** Either party may terminate this contract immediately upon material breach by the other party.
- 4.6 **Governing Law and Dispute Resolution.** The laws of Denmark govern this agreement, disregarding choice of law rules. If a dispute cannot be settled by negotiation between parties, it will be settled by the ordinary courts in that country.

5. Attachments:

The following attachments are part of this agreement:

Attachment A: Recipient's request for support

6. Agreed to and Accepted by:

Date: October 23, 2023

On behalf of Recipient:

DocuSigned by:
Tanja Thybo
E8906967344243C...

Name: Tanja Thybo

Title: ph.d., Chef for Forskning & Viden

Date: oktober 24, 2023

On behalf of Recipient:

DocuSigned by:
Claus Richter
21B32353305441A...

Name: Claus Richter

Title: CEO

Date: October 24, 2023

On behalf of Novo Nordisk:

DocuSigned by:
Christian Klyver Tikkanen
6086C4285774410

Name: Christian Klyver Tikkanen

Title: Sr. Market Access Manager & RareD lead

Date: October 24, 2023

On behalf of Novo Nordisk:

DocuSigned by:
Markus Peter Hochmuth
D6C3B77D06B64DC...

Name: Markus Peter Hochmuth

Title: Sr. Director, head of MAPA, Rare D. & In

Attachment A: Recipient's Request for Support

1. Copy of the Recipient's sponsorship request

Til
Christian Klyver Tikkanen
Novo Nordisk Denmark A/S

Ansøgning om støtte til fortsat udvikling af "Diabetestal.nu - Bred formidling af kvaliteten i behandlingen af diabetes i Danmark"

Tak for jeres støtte til udviklingen af diabetestal.nu, som vi lancerede 1. april 2023.

Diabetestal.nu er blevet taget godt imod af såvel mennesker med diabetes, politikere, sundhedsprofessionelle, journalister og medicinalindustrien. Vi har desuden brugt dashboardet til at udarbejde vores årspublikation, som kan findes her:

https://diabetes.dk/media/gktagxu3/_diabetes_%C3%A5rs-publikation_web.pdf.

Vi mener, at lige adgang til data skaber det bedste grundlag for dialog og forbedring af kvaliteten i diabetesbehandlingen. Vi håber også, at I vil gøre brug af diabetestal.nu.

Udviklingsarbejdet blev udført af IQVIA og kostede 2.297.463 kr. + moms. Hertil kom interne ressourcer på 1 FTE, som blev dækket af Diabetesforeningen. Vi modtog i forbindelse med udviklingen i alt støtte på 2.075.000 kr. + moms.

Som lovet vil diabetestal.nu blive opdateret fire gange årligt med nye tal fra det forrige kvartal, og kan gratis tilgås af alle brugere. Diabetesforeningen har indgået en aftale med IQVIA om varetagelsen af denne del af diabetestal.nu. Dette omfatter hvert kvartal en ny ansøgning til sundhedsdatastyrelsen, rensning og tilrettelægning af data, samt aggregering af data på forskermaskinen før overførslen til diabetestal.nu. Herefter følger en QC-procedure.

Sideløbende ønsker vi at videreudvikle diabetestal.nu visuelt og funktionelt og tilføje flere indikatorer for at forbedre dashboardets tilgængelighed og indhold. Endelig vil vi markedsføre diabetestal.nu overfor behandlere og kommuner omkring 1. oktober 2023 i forbindelse med data refresh.

Dette forventer vi vil koste (DKK):

0,3 FTE, projektleder Diabetesforeningen	246.000
160 timer, marketingsmedarbejder, Diabetesforeningen	68.000
320 timer data scientist, IQVIA	540.000
160 timer, konsulent/developer, IQVIA	146.000
I alt	1.000.000

Vi søger derfor Novo Nordisk Denmark A/S om et **sponsorat på op til kr. 500.000** til udviklingen af diabetestest.nu i 2023.
Beløbet tillægges moms.

Med venlig hilsen



Tanja Thybo, ph.d., Chef for Forskning & Viden

2. Activity timelines and budget

Dette forventer vi vil koste (DKK):

0,3 FTE, projektleder Diabetesforeningen	246.000
160 timer, marketingsmedarbejder, Diabetesforeningen	68.000
320 timer data scientist, IQVIA	540.000
160 timer, konsulent/developer, IQVIA	146.000
I alt	1.000.000

Vi søger derfor Novo Nordisk Denmark A/S om et **sponsorat på op til kr. 500.000** til udviklingen af diabetestest.nu i 2023.
Beløbet tillægges moms.

